Home > Formulary : Paediatric > Paediatric Chapters > 5. Infections >
BNSSG Paediatric Joint Formulary
5.6 Viral infection
Last edited: 14-02-2024
5.6.1 Hepatitis
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
5.6.2 Hepatitis B, chronic
Peginterferon alfa (parenteral) (TLS Red)
5.6.3 Hepatitis C, chronic
Peginterferon alfa (parenteral) (TLS Red)
- NICE TA300 Peginterferon alfa and ribavirin for the treatment of chronic Hepatitis C in children and young people
Ribavirin (oral) (TLS Red)
- NICE TA300 Peginterferon alfa and ribavirin for the treatment of chronic Hepatitis C in children and young people
5.6.4 Herpesvirus infections
Nucleoside Analogues
Aciclovir (oral) (TLS Green)
Aciclovir (parenteral) (TLS Red)
- Secondary care restricted, see local guidelines
Alternatives:
Valaciclovir (oral) (TLS Red)
- Restricted, see local guidelines
5.6.5 Herpesvirus infections, cytomegalovirus
Non-nucleoside Pyrophosphate Analogues
Foscarnet sodium (parenteral) (TLS Red)
- Secondary care restricted, see local guidelines
Nucleoside Analogues
Cidofovir (parenteral) (TLS Red)
- Secondary care restricted, see local guidelines
Ganciclovir (parenteral) (TLS Red)
- Secondary care restricted, see local guidelines
Valganciclovir (oral) (TLS Red)
- Secondary care restricted, see local guidelines
Valganciclovir solution (oral) (TLS Red)
- Secondary care restricted, see local guidelines
5.6.6 HIV infection
HIV Fusion Inhibitors
Enfuvirtide (parenteral) (TLS Red)
HIV Integrase Inhibitors
Dolutegravir (oral) (TLS Red)
Abacavir / Dolutegravir / Lamivudine (oral) (TLS Red)
Non-nucleoside Reverse Transcriptase Inhibitors
Efavirenz (oral) (TLS Red)
Etravirine (oral) (TLS Red)
Nevirapine (oral) (TLS Red)
Rilpivirine (oral) (TLS Red)
Nucleoside Reverse Transcriptase Inhibitors
Abacavir (oral) (TLS Red)
Didanosine (oral) (TLS Red)
Emtricitabine (oral) (TLS Red)
Lamivudine (oral) (TLS Red)
Tenofovir disoproxil (oral) (TLS Red)
Zidovudine (oral & parenteral) (TLS Red)
Protease Inhibitors (HIV)
Atazanavir (oral) (TLS Red)
Darunavir (oral) (TLS Red)
Ritonavir (oral) (TLS Red)
5.6.7 Influenza
See NICE TA158
As per NICE TA168 Influenza (treatment)
Neuraminidase inhibitors
Oseltamivir (oral) (TLS Green)
- Restricted, see local guidelines
Zanamivir (oral) (TLS Green)
- Restricted, see local guidelines
Zanamivir (intravenous) (TLS Red)
- Secondary care restricted in line with Public Health England Guidance for severe/complicated influenza (treatment), see local guidelines
5.6.8 Respiratory Syncytial virus
Palivizumab (parenteral) (TLS Red)
- NHSE SSC 2616 End of 2023-24 Respiratory Syncytial Virus (RSV) season and cessation of access to palivizumab passive immunisation against RSV in at risk pre-term infants